The Terminal (Catalytic) Adenosine of the HIV LTR Controls the Kinetics of Binding and Dissociation of HIV Integrase Strand Transfer Inhibitors
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Specific HIV integrase strand transfer inhibitors are thought to bind to the integrase active site, positioned to coordinate with two catalytic magnesium atoms in a pocket flanked by the end of the viral LTR. A structural role for the 3' terminus of the viral LTR in the inhibitor-bound state has not previously been examined. This study describes the kinetics of binding of a specific strand transfer inhibitor to integrase variants assembled with systematic changes to the terminal 3' adenosine. Kinetic experiments are consistent with a two-step binding model in which there are different functions for the terminal adenine base and the terminal deoxyribose sugar. Adenine seems to act as a "shield" which retards the rate of inhibitor association with the integrase active site, possibly by acting as an internal competitive inhibitor. The terminal deoxyribose is responsible for retarding the rate of inhibitor dissociation, either by sterically blocking inhibitor egress or by a direct interaction with the bound inhibitor. These findings further our understanding of the details of the inhibitor binding site of specific strand transfer inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The displaced vDNA nucleotide forms a stacking interaction with the metal chelating core of the inhibitor, greatly enhancing the strength of binding35,36,163.”
From Structure and function of retroviral integrase (2022) · cites this paper as [163]
In the citing paper
“Because the 3’ adenosine must vacate its normal position to allow inhibitor binding, the INSTIs display slow binding kinetics163.”
From Structure and function of retroviral integrase (2022) · cites this paper as [163]
Citations
Cites
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Integrase inhibitors to treat HIV/Aids
Pommier, Y., Johnson, A. A., & Marchand, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1660 · Cited by 688
HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer
Engelman, A., Mizuuchi, K., & Craigie, R. (1991) · Cell · doi:10.1016/0092-8674(91)90297-c · Cited by 655
Goldgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., Endo, T., Murai, H., & Davies, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13040 · Cited by 496
Grobler, J. A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A. S., Wolfe, A., Egbertson, M., Bourgeois, M., Melamed, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092056199 · Cited by 399
Retroviral DNA integration directed by HIV integration protein in vitro
Bushman, F. D., Fujiwara, T., & Craigie, R. (1990) · Science · doi:10.1126/science.2171144 · Cited by 338
Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P., Egbertson, M. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402357101 · Cited by 333
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques
Hazuda, D. J., Young, S. D., Guare, J. P., Anthony, N. J., Gomez, R. P., Wai, J. S., Vacca, J. P., Handt, L., Motzel, S. L., Klein, H. J., et al. (2004) · Science · doi:10.1126/science.1098632 · Cited by 285
Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine
Furfine, E. S., Harmon, M. F., Paith, J. E., & Garvey, E. P. (1993) · Biochemistry · doi:10.1021/bi00084a017 · Cited by 279
Research works printed but not linked: 3
- Cooper, D. A., Gatell, J., Rockstroh, J., Katlama, C., Yeni, P., Lazzarin, A., Chen, J., Isaacs, R., Teppler, H., Nguyen, B.Y., and Group, B.S.(2007) Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safey of raltegravir (MK-0518), a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus, presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, p 105LB, Denver, CO, Feb 5−8, 2006.
- Kawaguchi, I., Ishikawa, T., Ishibashi, M., Irie, S., and Kakee, A.(2006) Safety and Pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers, presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI), Feb 5−8, Denver, CO, Poster #580.
- Bourke, D. G., Chalmers, D. K., Jones, R. D., Crosby, I. T., and Wielens, J.(2001) Molecular modeling of inhibitors in the active site of HIV-1 integrase, presented at the 14th International Conference on Antivirus Research, Seattle, WA, April, 2001.
Cited by
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Hare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
“Measurements using in vitro assembled HIV-1 IN-DNA complexes showed that the 3 -deoxyadenosine controls INSTI binding, and that removing the nucleotide drastically increases the kinetics of INSTI binding and dissociation (Langley et al., 2008).”
BackgroundMethodLesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-11 · Cited by 226
“plexes were performed by methods similar to published methods (32).”
BackgroundMethodStructure-based modeling of the functional HIV-1 intasome and its inhibition
Krishnan, L., Li, X., Naraharisetty, H. L., Hare, S., Cherepanov, P., & Engelman, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002346107 · Cited by 191
“The mechanism of INSTIIN binding has been difficult to ascertain in the absence of intasome structural information.”
BackgroundResultInfluentialNowicka-Sans, B., Gong, Y.-F., McAuliffe, B. V., Dicker, I. B., Ho, H., Zhou, N., Eggers, B. J., Lin, P., Ray, N., Wind‐Rotolo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00426-12 · Cited by 139
“This kind of complex binding has been described for small-molecule HIV integrase inhibitors (23).”
Self-citationStructure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Structural biology of retroviral DNA integration
Li, X., Krishnan, L., Cherepanov, P., & Engelman, A. (2011) · Virology · doi:10.1016/j.virol.2010.12.008 · Cited by 112
“Elegant dissection of individual sequence elements highlighted roles for the vDNA end and in particular, the 3′ adenosine, in INSTI binding (Dicker et al., 2007; Langley et al., 2008).”
BackgroundStructural basis of second-generation HIV integrase inhibitor action and viral resistance
Cook, N. J., Li, W., Berta, D., Badaoui, M., Ballandras-Colas, A., Nans, A., Kotecha, A., Rosta, E., Engelman, A. N., & Cherepanov, P. (2020) · Science · doi:10.1126/science.aay4919 · Cited by 108
Structural basis for strand-transfer inhibitor binding to HIV intasomes
Passos, D. O., Li, M., Jóźwik, I. K., Zhao, X. Z., Santos-Martins, D., Yang, R., Smith, S. J., Jeon, Y., Forli, S., Hughes, S. H., et al. (2020) · Science · doi:10.1126/science.aay8015 · Cited by 106
Inhibiting the HIV Integration Process: Past, Present, and the Future
Santo, R. D. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400674a · Cited by 112
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
“Alterations of viral DNA sequence, especially the terminal deoxyadenylate residue, also alter INSTI dissociative half-life (91), although to date, LTR sequence changes have not been implicated in INSTI resistance.”
BackgroundXue, W., Jin, X., Ning, L., Wang, M., Liu, H., & Yao, X. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300541c · Cited by 74
Resistance to HIV-1 integrase inhibitors: A structural perspective
Mouscadet, J. F., Delelis, O., Marcelin, A., & Tchertanov, L. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.05.001 · Cited by 81
Barreca, M. L., Iraci, N., Luca, L. D., & Chimirri, A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900166 · Cited by 70
A Dynamic Model of HIV Integrase Inhibition and Drug Resistance
Perryman, A. L., Forli, S., Morris, G. M., Burt, C., Cheng, Y., Palmer, M. J., Whitby, K., McCammon, J. A., Phillips, C., & Olson, A. J. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.01.033 · Cited by 63
Rhodes, D. I., Peat, T. S., Vandegraaff, N., Jeevarajah, D., Le, G. T., Jones, E. D., Smith, J. A., Coates, J. A. V., Winfeld, L. J., Thienthong, N., et al. (2011) · Antiviral chemistry & chemotherapy · doi:10.3851/imp1716 · Cited by 52
“[11] led to a model in which the adenine opens or closes the active site for DNA processing.”
BackgroundJohnson, B. C., Métifiot, M., Pommier, Y. G., & Hughes, S. H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05292-11 · Cited by 48
“1) using a scintillation proximity assay (37).”
BackgroundBera, S., Pandey, K. K., Vora, A. C., & Grandgenett, D. P. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.04.007 · Cited by 43
Métifiot, M., Maddali, K., Johnson, B. C., Hare, S., Smith, S. J., Zhao, X. Z., Marchand, C., Burke, T. R., Hughes, S. H., Cherepanov, P., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb300471n · Cited by 44
Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
Trivedi, J. S., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00480-3 · Cited by 60
Garvey, E. P., Schwartz, B. J., Gartland, M. J., Lang, S., Halsey, W. S., Sathe, G. M., Carter, H. L., & Weaver, K. L. (2009) · Biochemistry · doi:10.1021/bi802141y · Cited by 40
Xue, W., Liu, H., & Yao, X. (2011) · Journal of Computational Chemistry · doi:10.1002/jcc.22887 · Cited by 39
Lü, H., Iuliano, J. N., & Tonge, P. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.002 · Cited by 39
Pandey, K. K., Bera, S., Vora, A. C., & Grandgenett, D. P. (2010) · Biochemistry · doi:10.1021/bi100514s · Cited by 22
“affinity and is subsequently converted to a higher affinity complex upon isomerization of the IN-DNA complex (41, 42).”
BackgroundLin, Z., Cantone, J. L., Lu, H., Nowicka-Sans, B., Protack, T., Tian, Y., Yang, H., Liu, Z., Drexler, D. M., Regueiro‐Ren, A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005990 · Cited by 20
Self-citationPathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance
Malet, I., Ambrosio, F. A., Subra, F., Herrmann, B., Leh, H., Bouger, M.-C., Artese, A., Katlama, C., Talarico, C., Romeo, I., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx529 · Cited by 21
HIV‐1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations
Mouscadet, J. F., Arora, R., André, J. R., Lambry, J., Delelis, O., Malet, I., Marcelin, A., Cálvez, V., & Tchertanov, L. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.970 · Cited by 22
“A recent biochemical study (Langley et al., 2008) carried out with a different IN inhibitor concluded that the terminal adenosine of the viral LTR controlled the binding of strand transfer inhibitors.”
BackgroundBarski, M. S., Vanzo, T., Zhao, X. Z., Smith, S. J., Ballandras-Colas, A., Cronin, N., Pye, V. E., Hughes, S. H., Burke, T. R., Cherepanov, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25284-1 · Cited by 19
“For the expression of LEDGF/ΔIBDB56γ, the previously described pET28a(+)SUMO-H6P-LEDGF/ΔIBDPPP2R5C(11-380) construct was used9.”
BackgroundScintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration
Grobler, J. A., Stillmock, K. A., & Hazuda, D. J. (2009) · Methods · doi:10.1016/j.ymeth.2009.03.002 · Cited by 15
HIV-1 Integrase Strand Transfer Inhibitors Stabilize an Integrase–Single Blunt-Ended DNA Complex
Bera, S., Pandey, K. K., Vora, A. C., & Grandgenett, D. P. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.043 · Cited by 13
Unprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir
Ammar, F. F., Abdel‐Azeim, S., Zargarian, L., Hobaika, Z., Maroun, R. G., & Fermandjian, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040223 · Cited by 11
“Noteworthy, RAL makes van der Waals contacts with both the invariant 59C(4)pA(3)39step known for its functional importance at the LTR end [34,61] and the guanine G(24) facing the cytosine C(4) of this step.”
BackgroundPandey, K. K., Bera, S., Korolev, S., Campbell, M. A., Yin, Z., Aihara, H., & Grandgenett, D. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.573311 · Cited by 9
Hikichi, Y., Burdick, R. C., Patro, S. C., Ding, S.-Y., Luke, B. T., Clark, E., Ablan, S. D., Wu, X., Pathak, V. K., & Freed, E. O. (2025) · Science Advances · doi:10.1126/sciadv.adz8980 · Cited by 12
HIV-1 Integrase Drug Discovery Comes of Age
Demeulemeester, J., Maeyer, M. D., & Debyser, Z. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_33 · Cited by 9
Brief Histories of Retroviral Integration Research and Associated International Conferences
Grandgenett, D. P., & Engelman, A. (2024) · Viruses · doi:10.3390/v16040604 · Cited by 8
“…Dicker employed a scintillation proximity assay with tritiated INSTI BMS-641493 to investigate the role of LTR base residues in INSTI binding, concluding that the invariant adenosine slowed the rate of INSTI association and also the rate of INSTI dissociation from the nucleoprotein complex [118].”
MethodRaltegravir flexibility and its impact on recognition by the HIV‐1 IN targets
Arora, R., de Beauchêne, I. C., Polański, J., Laine, É., & Tchertanov, L. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2277 · Cited by 7
“Terminal bases of the vDNA play a role in both catalytic efficiency (Sherman et al., 1992; Johnson et al., 2006) and inhibitor binding (Dicker et al., 2007; Johnson et al., 2007; Langley et al., 2008).”
BackgroundAmmar, F. F., Hobaika, Z., Abdel‐Azeim, S., Zargarian, L., Maroun, R. G., & Fermandjian, S. (2015) · FEBS Open Bio · doi:10.1002/2211-5463.12025 · Cited by 7
The HIV-1 Integrase: Modeling and Beyond
Arora, R., & Tchertanov, L. (2013) · InTech eBooks · doi:10.5772/52344 · Cited by 5
“Terminal bases of the viral DNA play a role in both catalytic efficiency [87,88] and inhibitor binding [89-91].”
BackgroundDicker, I. B., Walker, M. A., Lin, Z., Terry, B., Pajor, L., Zheng, M., Naidu, B. N., Banville, J., Meanwell, N. A., & Krystal, M. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch19
Self-citationDarazi, P. E. (2021) · theses.fr (ABES) · doi:10.70675/7bb07492ze915z4ca3z845fzba3bb62a3520 · Cited by 1
Non-integrase mechanisms for dolutegravir resistance
Engelman, A. (2026) · Retrovirology · doi:10.1186/s12977-026-00678-5 · Cited by 1
“INSTI binding rates to HIV-1 IN-viral DNA complexes in vitro have been most carefully described for a pre-clinical compound from Bristol-Myers Squibb [68].”
BindingDB Entry 50006022: Inhibiting the HIV integration process: past, present, and the future.
BindingDB (2020) · UC San Diego · doi:10.7270/q2qc06gp
Metadata
- Authors
- Langley, D. R., Samanta, H. K., Lin, Z., Walker, M. A., Krystal, M. R., & Dicker, I. B.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Dicker, Ira B.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-11-08
- Volume
- 47
- Issue
- 51
- Pages
- 13481-13488
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2042656735
- Cited by
- 42
- References
- 43
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 4
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- HIV integrase, integrase strand transfer inhibitors, HIV long terminal repeat, competitive inhibition
- MeSH terms
- Adenosine, Binding, Competitive, Chemistry, Pharmaceutical, HIV, Kinetics, Models, Chemical, Models, Molecular, Molecular Conformation, Protein Binding, Temperature, HIV Long Terminal Repeat, HIV Integrase, HIV Integrase Inhibitors, Catalytic Domain, 3' Untranslated Regions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.